article thumbnail

EGFR inhibitor could provide major advance in lung cancer

European Pharmaceutical Review

TAGRISSO as a combination treatment with chemotherapy was recently approved in the US, based on data from the FLAURA2 Phase III trial. Research predicts 2029 small molecule oncology market leaders The post EGFR inhibitor could provide major advance in lung cancer appeared first on European Pharmaceutical Review.

article thumbnail

Eisai joins the ADC golden rush

Pharmaceutical Technology

The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload. GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). targeting ADC.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Antibody-drug conjugates: paving the future of oncology clinical development

European Pharmaceutical Review

Yet as the market continues to recognise the value of these treatments, especially with them having “clear benefits over current monotherapy and combination therapy options in cancer treatment”, it is unsurprising that GlobalData’s research predicted the ADC oncology therapy market will value more than $36 billion by 2029.

article thumbnail

AstraZeneca acquires TeneoTwo in $1.3bn deal to broaden haematology portfolio

Pharmaceutical Technology

Blincyto has provided a strong positive signal to demonstrate the clinical and commercial viability of BiTEs, with 2021 company-reported global sales of $542 million and GlobalData’s analyst consensus forecast projecting peak annual sales of $771 million by 2029, thereby sparking further industry interest in this field. months vs. 4.0

article thumbnail

Future of Bispecific Antibody: Exploring the Rise in Approvals

Roots Analysis

One area of interest is in oncology , where bispecific antibodies can be used to target two different antigens at the same time, leading to improved efficacy and reduced toxicity compared to traditional chemotherapy. during the period 2023-2035.

article thumbnail

7 Best DRY MOUTH lozenges for saliva production

Druggist

Treatment, for example, chemotherapy and radiotherapy. link] Available at: [link] Accessed on 10/03/2029. ?ysik One of the most common reasons for dry mouth is dehydration. Other common reasons for dry mouth include: Taking certain drugs (see the next paragraph). List of common drugs that cause dry mouth. Sci Rep 9, 17648 (2019).